Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review
This systematic review sought to summarise data on the efficacy of vonoprazan, a novel potassium-competitive acid blocker, as compared with a proton pump inhibitor (PPI)-based regimen for first-line treatment of Helicobacter pylori eradication. A systematic literature search of MEDLINE, EMBASE, an...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Penerbit Universiti Kebangsaan Malaysia
2020
|
| Online Access: | http://journalarticle.ukm.my/15472/1/15.pdf |
| _version_ | 1796932263641874432 |
|---|---|
| author | Nur Azlina Mohd Fahami, Nur Aishah Che Roos, |
| author_facet | Nur Azlina Mohd Fahami, Nur Aishah Che Roos, |
| author_sort | Nur Azlina Mohd Fahami, |
| collection | UKM |
| description | This systematic review sought to summarise data on the efficacy of vonoprazan, a novel potassium-competitive acid
blocker, as compared with a proton pump inhibitor (PPI)-based regimen for first-line treatment of Helicobacter pylori
eradication. A systematic literature search of MEDLINE, EMBASE, and the Cochrane Library using the primary
keywords ‘vonoprazan’, ‘takecab’, ‘TAK-438’, ‘potassium’, ‘competitive’, ‘potassium-competitive’, ‘Helicobacter’, and
‘pylori’ was performed. Studies were included if they evaluated the eradication rate between vonoprazan-based and
PPI-triple therapies. Overall, 15 studies were included in this review (three randomised controlled trials (RCTs), 12
non-RCTs). Both the included RCTs and non-RCTs showed a statistically significant superiority of vonoprazan-based
therapy to PPI-based therapy as esomeprazole. Only 11 of the included studies were deemed as having good quality.
In two RCTs, vonoprazan-based therapy showed a statistically significant superiority over PPI-based therapy with H.
pylori eradication rates in excess of 90% (p-value < 0.001). Meanwhile, observational studies demonstrated first-line
therapy eradication rates ranging between 85.0 and 95.5% in the vonoprazan-based group versus between 66.8 and
86.7% in the PPI-based group with statistical significance. In conclusion, vonoprazan-based triple therapy provided
superior efficacy in H. pylori eradication versus PPI-based triple therapy. Vonoprazan shows a promising ability as a
potent and long-acting, acid-reducing agent, with some potential advantages over traditional PPIs, particularly in the
treatment of H. pylori infection. As a relatively new agent, whether vonoprazan is appropriate and safe for long-term or
life-long use remains to be determined in the near future. |
| first_indexed | 2024-03-06T04:30:12Z |
| format | Article |
| id | ukm.eprints-15472 |
| institution | Universiti Kebangsaan Malaysia |
| language | English |
| last_indexed | 2024-03-06T04:30:12Z |
| publishDate | 2020 |
| publisher | Penerbit Universiti Kebangsaan Malaysia |
| record_format | dspace |
| spelling | ukm.eprints-154722020-10-30T04:48:25Z http://journalarticle.ukm.my/15472/ Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review Nur Azlina Mohd Fahami, Nur Aishah Che Roos, This systematic review sought to summarise data on the efficacy of vonoprazan, a novel potassium-competitive acid blocker, as compared with a proton pump inhibitor (PPI)-based regimen for first-line treatment of Helicobacter pylori eradication. A systematic literature search of MEDLINE, EMBASE, and the Cochrane Library using the primary keywords ‘vonoprazan’, ‘takecab’, ‘TAK-438’, ‘potassium’, ‘competitive’, ‘potassium-competitive’, ‘Helicobacter’, and ‘pylori’ was performed. Studies were included if they evaluated the eradication rate between vonoprazan-based and PPI-triple therapies. Overall, 15 studies were included in this review (three randomised controlled trials (RCTs), 12 non-RCTs). Both the included RCTs and non-RCTs showed a statistically significant superiority of vonoprazan-based therapy to PPI-based therapy as esomeprazole. Only 11 of the included studies were deemed as having good quality. In two RCTs, vonoprazan-based therapy showed a statistically significant superiority over PPI-based therapy with H. pylori eradication rates in excess of 90% (p-value < 0.001). Meanwhile, observational studies demonstrated first-line therapy eradication rates ranging between 85.0 and 95.5% in the vonoprazan-based group versus between 66.8 and 86.7% in the PPI-based group with statistical significance. In conclusion, vonoprazan-based triple therapy provided superior efficacy in H. pylori eradication versus PPI-based triple therapy. Vonoprazan shows a promising ability as a potent and long-acting, acid-reducing agent, with some potential advantages over traditional PPIs, particularly in the treatment of H. pylori infection. As a relatively new agent, whether vonoprazan is appropriate and safe for long-term or life-long use remains to be determined in the near future. Penerbit Universiti Kebangsaan Malaysia 2020-06 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/15472/1/15.pdf Nur Azlina Mohd Fahami, and Nur Aishah Che Roos, (2020) Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review. Sains Malaysiana, 49 (6). pp. 1371-1380. ISSN 0126-6039 http://www.ukm.my/jsm/malay_journals/jilid49bil6_2020/KandunganJilid49Bil6_2020.html |
| spellingShingle | Nur Azlina Mohd Fahami, Nur Aishah Che Roos, Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title | Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title_full | Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title_fullStr | Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title_full_unstemmed | Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title_short | Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy: a systematic review |
| title_sort | vonoprazan and proton pump inhibitors in helicobacter pylori eradication therapy a systematic review |
| url | http://journalarticle.ukm.my/15472/1/15.pdf |
| work_keys_str_mv | AT nurazlinamohdfahami vonoprazanandprotonpumpinhibitorsinhelicobacterpylorieradicationtherapyasystematicreview AT nuraishahcheroos vonoprazanandprotonpumpinhibitorsinhelicobacterpylorieradicationtherapyasystematicreview |